Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Off-Target Reactivity Assessment Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The clinical translation of T cell therapies is hindered by unpredictable off-target toxicities and inherent basal signaling. Creative Biolabs' Off-Target Reactivity Assessment Service is designed to address these critical safety challenges for autologous TAC-T cell products. We employ a mechanism-driven evaluation combining multi-omics profiling and high-resolution functional assays to quantify antigen specificity. This integrated approach delivers definitive data on the "activation gap," empowering you with the scientific evidence to de-risk development, justify a superior safety profile, and confidently advance your TAC-T candidate.

Introduction

Off-target reactivity refers to the unintended recognition by engineered T cells of antigens that are structurally similar to, but distinct from, the intended tumor-specific antigen, leading to the activation of T cells against healthy tissues. In the context of T cell-based immunotherapies, such off-target effects pose significant clinical hazards, including severe and potentially fatal toxicities, such as neurotoxicity, cardiotoxicity, and colitis, as evidenced in trials targeting antigens like MAGE-A3, MART-1, and CEA, where cross-reactivity with self-antigens expressed in normal cells resulted in adverse outcomes and limited therapeutic safety.

Fig.1 Strategies for anticipating on-target and off-tumor effects. (OA Literature) Fig.1 Assessment of target-mediated and off-target immune toxicities.¹

Off-Target Reactivity Assessment Service at Creative Biolabs

Creative Biolabs delivers a definitive preclinical validation framework to ensure your TAC-T cells maintain a quiescent state prior to encountering their specific tumor target. By elucidating how the TAC receptor engages the endogenous TCR machinery, we generate conclusive evidence confirming the lack of tonic signaling and the high-fidelity antigen discrimination that safeguards against severe off-target adverse events.

What We Can Offer

Our Off-Target Reactivity Assessment Service delivers a multi-layered safety evaluation for your TAC-T cell therapy. We integrate unbiased proteomic screening, functional cellular validation, and mechanistic analyses to quantify specificity, de-risk off-target toxicity, and provide definitive data for clinical advancement.

Featured services of off-target reactivity assessment service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Sequence data for the TAC scFv binding domain and receptor construct.
Target antigen expression profiles and identified potential cross-reactive candidates.
Specific HLA-typing requirements for the autologous T cell background.

Key Steps:

Workflow of off-target reactivity assessment service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will be provided with a Comprehensive Safety Threshold Report that quantifies the half-maximal effective concentration (EC50) differential between the intended target and identified off-target peptides.

Key Advantages

Donor-Tailored Multi-Omic Basal Profiling: We conduct integrated transcriptomic and proteomic analysis on your TAC-T cells to establish donor-specific baseline activity profiles and confirm a true resting state.
Quantitative Cellular Safety Thresholding: We measure activation kinetics across a diverse panel of primary human cell types to determine and contrast the half-maximal effective concentrations (EC50) for intended target versus off-target interactions.
Mechanistic Toxicity Investigation and Reporting: Our analysis provides a detailed molecular explanation for any observed cross-reactivity, delivering actionable insights for the precise re-engineering of receptor binding domains and affinity optimization.

FAQs

Q1: How does your service differentiate between tonic signaling and low-level cross-reactivity?

A1: Our platform employs a multi-parametric approach to distinguish these distinct risks. We identify tonic signaling through transcriptional analysis of early activation markers, combined with basal surface expression of CD69. To define low-affinity cross-reactivity, we perform functional assays in the presence of target-mimicking peptides; activation events observed solely with these peptides are quantified through dose-response analysis, providing a clear threshold for off-target engagement.

Q2: Can you perform assessments on autologous T cells with specific HLA backgrounds?

A2: Of course. Our service includes access to a comprehensive panel of HLA-typed antigen-presenting cells and primary human cell lines covering common and rare HLA alleles. This ensures that your TAC-T product's off-target risk is evaluated within a clinically relevant immunological context, directly applicable to your intended patient population.

Why Choose Us?

Our expertise is uniquely tailored to the specific biology of the TAC receptor. We move beyond generic screening by defining the Selectivity Index, a rigorous quantitative measure of on-target specificity versus proteomic cross-reactivity. This enables us to deliver critical data demonstrating that TAC-T cells engage targets through organized synapse formation, thereby providing a scientifically robust validation of their superior safety profile over conventional, highly tonic CAR-T constructs.

Customer Reviews

"We were struggling with CAR-T exhaustion. Using the Creative Biolabs assessment platform, we successfully transitioned to a TAC-based receptor and proved the absence of basal activation."

— Prof. Ma*in K.

"Using Creative Biolabs' Off-Target Reactivity Assessment Service in our research has significantly improved our ability to distinguish between tonic signaling and true antigen-dependent activation. The high-resolution imaging was instrumental in our recent publication."

— Dr. Al*rt S.

"The EC50 gap analysis provided by Creative Biolabs helped us define a safety threshold for our TAC-T cells. This precise data was specifically requested by regulatory reviewers and facilitated our clinical advancement."

— Sarah L*on.

How to contact us?

Creative Biolabs is committed to delivering a comprehensive, data-backed safety assessment for your autologous TAC-T cell therapy. Our experts provide critical insights through comprehensive analyses, including baseline signaling characterization and proteome-wide off-target screening, to ensure your candidate progresses with confidence.

Contact our specialists to discuss how we can support your program.

Reference

Baulu, Estelle et al. "TCR-engineered T cell therapy in solid tumors: State of the art and perspectives." Science advances vol. 9,7 (2023): eadf3700. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1126/sciadv.adf3700

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.